To elucidate the relationship between regional myocardial adrenergic innervation and left venticular hypertrophy in patients with hypertrophic cardiomyopathy(HCM), simultaneous iodine-123 metaiodobenzylguanidine (123IMIBG)and thallium-201 (201T1) myocardial scintigraphies were performed in 21 patients with HCM. In 7 patients both 123I-MIBG and 201T1 images showed a normal distribution pattern, and in 13 patients 202T1 showed a normal distribution,but 123I-MIBG showed a low distribution or defect. Myocardial uptake of 123I-MIBG was reduced even in the segments where myocardial hypertrophy was confirmed by the échocardiographie method. The incidence of a low distribution or defect in 123I-MIBG was significantly higher in the posterior,lateral and apical segments than in the anterior and septal segments in HCM patients (each, p <0.01). The difference in the distribution pattern between 123I-MIBG and 201T1 may reflect adrenergic nerve dysfunction. The disorder of adrenergic innervation seems to precede myocardial damage. From these findings, we conclude that a good correlation between myocardial adrenergic innervation and left ventricular hypertrophy is not necessarily observed, and the difference in distribution pattern between 123I-MIBG and 20IT1 usually takes place in the advanced stage of HCM.

Keywords:
Iodine-123 metaiodobenzylguanidine, Thallium-201, Hypertrophie cardiomyopathy, Ventricular hypertrophy, left, Cardiac adrenergic innervation
This content is only available via PDF.
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.